Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), FiscalAI reports. The firm had revenue of $7.56 million for the quarter, compared to analysts’ expectations of $11.02 million.
Aquestive Therapeutics Stock Up 2.9%
Shares of NASDAQ AQST traded up $0.11 during trading hours on Tuesday, reaching $3.88. 2,029,780 shares of the stock traded hands, compared to its average volume of 2,917,538. The company has a market capitalization of $486.98 million, a P/E ratio of -5.97 and a beta of 1.49. The company’s 50-day simple moving average is $4.64 and its two-hundred day simple moving average is $4.20. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $6.85.
Analyst Ratings Changes
A number of equities research analysts recently commented on AQST shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.60.
Check Out Our Latest Stock Report on AQST
Insider Transactions at Aquestive Therapeutics
In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the transaction, the chief executive officer owned 627,317 shares in the company, valued at $2,647,277.74. The trade was a 3.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,750 shares of company stock worth $271,675 over the last ninety days. Insiders own 6.81% of the company’s stock.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.
Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Aquestive Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
